<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646850</url>
  </required_header>
  <id_info>
    <org_study_id>18-14061</org_study_id>
    <nct_id>NCT04646850</nct_id>
  </id_info>
  <brief_title>Long-term Treatment With the Ketogenic Diet in Epilepsy</brief_title>
  <official_title>Long-term Treatment With the Ketogenic Diet in Epilepsy and Epilepsy-related Rare Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide a comprehensive assessment of long-term treatment with the ketogenic&#xD;
      diet, a medical diet with high fat and low carbohydrate intake, focusing on safety and&#xD;
      cardiovascular implications. We will assess patients with epilepsy or one of two rare&#xD;
      metabolic diseases; glucose transporter type 1 deficiency syndrome (GLUT1 DS) or pyruvate&#xD;
      dehydrogenase complex deficiency (PDHD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular risk after long-term treatment with the ketogenic diet</measure>
    <time_frame>2018-2022</time_frame>
    <description>Color duplex ultrasound</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Epilepsy</condition>
  <condition>GLUT1DS1</condition>
  <condition>PDH Deficiency</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Color duplex ultrasound of the carotid arteries</intervention_name>
    <description>Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with the ketogenic diet (classical or modified) for epilepsy, GLUT1&#xD;
        deficiency or PDHD at The National Centre for Epilepsy - SSE for 5 years or longer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment with the ketogenic diet at the National Centre for Epilepsy (SSE) for 5&#xD;
             years or more&#xD;
&#xD;
          -  Able to travel from The National Centre for Epilepsy - SSE (Sandvika) to&#xD;
             Rikshospitalet (Gaustad) to perform procedures to investigate cardiovascular risk&#xD;
             factors&#xD;
&#xD;
          -  Willing to draw extra blood for research purposes&#xD;
&#xD;
          -  Willing to sign informed consent and participate in the study in accordance with the&#xD;
             study protocol&#xD;
&#xD;
          -  Willing to sign informed consent for blood samples to be included in research biobank&#xD;
             at the Department of Neurology, Oslo University Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-compliance with the dietary treatment for 6 months or longer or more than once per&#xD;
             month&#xD;
&#xD;
          -  Not possible to communicate with parents in Norwegian or English without interpreter&#xD;
&#xD;
          -  Patient not able to cooperate and lie still for about ten minutes during the carotid&#xD;
             ultrasound examination&#xD;
&#xD;
          -  Psychiatric/mental illness, alcohol or drug abuse or other factors making it&#xD;
             impossible to pursue the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anette Ramm-Pettersen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Anette Ramm-Pettersen</investigator_full_name>
    <investigator_title>Head of Child Neurology</investigator_title>
  </responsible_party>
  <keyword>Ketogenic dieting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Pyruvate Dehydrogenase Complex Deficiency Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

